- Report
- January 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- March 2024
- 196 Pages
Global
From €3251EUR$3,374USD£2,797GBP
€3612EUR$3,749USD£3,107GBP
- Report
- December 2022
- 153 Pages
Global
From €5059EUR$5,250USD£4,352GBP
- Report
- January 2022
- 60 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- August 2022
United States
From €1869EUR$1,940USD£1,608GBP
- Report
- August 2022
Global
From €1050EUR$1,090USD£903GBP
- Report
- February 2021
Global
From €2852EUR$2,960USD£2,453GBP
- Report
- April 2022
- 71 Pages
Global
From €3368EUR$3,495USD£2,897GBP
- Clinical Trials
- January 2020
- 658 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Report
- April 2021
- 40 Pages
Global
From €3850EUR$3,995USD£3,311GBP
- Report
- October 2023
- 91 Pages
Global
From €3500EUR$3,891USD£3,116GBP
Small Cell Lung Cancer (SCLC) is a type of lung cancer that is characterized by the rapid growth of malignant cells. It is the most aggressive form of lung cancer and accounts for approximately 10-15% of all lung cancer cases. Treatment for SCLC typically involves a combination of chemotherapy, radiation therapy, and surgery.
Drugs used to treat SCLC include chemotherapy agents such as cisplatin, etoposide, and carboplatin, as well as targeted therapies such as erlotinib and gefitinib. Immunotherapy is also being explored as a potential treatment option.
The SCLC drug market is highly competitive, with a number of companies developing and marketing drugs for the treatment of SCLC. Some of the major players in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
